Medical scheme racism report may ‘undermine' anti-fraud efforts, Discovery claims
Be among those who shape the future with knowledge. Uncover exclusive stories that captivate your mind and heart with our FREE 14-day subscription trial. Dive into a world of inspiration, learning, and empowerment. You can only trial once.
Show Comments ()
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
18 minutes ago
- Yahoo
Empeon Unveils New Technology Integrations to Help Drive Efficiency and Satisfaction Across Healthcare Workforces
Integrations with Equifax®, Human Interest and Streamline Verify Provide Income and Employment Verification, 401(k) Services and Exclusion Screening/License Checks, Respectively, to Help Support Facility Compliance and Employee Wellbeing MONTEBELLO, N.Y., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Empeon (the 'Company'), a human capital management software company focused on the healthcare industry, today announced new technology integrations with Equifax®, Human Interest and Streamline Verify to transform how healthcare providers manage their business and support their staff. These integrations expand Empeon's all-in-one, healthcare-focused platform with capabilities that include employment verification, 401(k) services and background/license checks, reinforcing the Company's mission to help healthcare organizations streamline operations, ease administrative workloads and proactively meet regulatory requirements. Empeon now offers access to The Work Number® from Equifax®, enabling automated and more secure income and employment verifications. The Work Number® helps simplify and accelerate the verification process for employees seeking loans, mortgages and other financial and government services, reducing the administrative burden on employers while helping simplify the verification process for employees. Empeon has also named Human Interest as its preferred 401(k) provider, delivering seamless, healthcare-specific retirement planning tools. The integration allows organizations to offer robust financial wellness benefits with minimal administrative overhead, helping to attract and retain top talent in a highly competitive labor market. Finally, to strengthen compliance and protect patient safety, Empeon's partnership with Streamline Verify introduces exclusion screening and continuous licensure monitoring. This integration helps employers to prevent credentialing gaps and maintain alignment with complex healthcare regulations, ensuring operational integrity at every level. Not only does Streamline Verify deliver Complete Automation through deep integrations, but it now introduces Intelligent Automation powered by data science—streamlining workflows, enabling smarter screenings, reducing false positives, and delivering faster, more precise results. 'As the healthcare industry continues to face ongoing staffing shortages and retention challenges, organizations need every advantage to remain competitive and sustainable,' said Morris Isaacson, EVP, Growth and Insights, Empeon. 'At Empeon, our mission is to simplify and strengthen healthcare workforce management so that organizations can do just that. By unifying core HR functions, including payroll, scheduling, benefits administration and more, we empower providers to operate more efficiently and give employees the tools they need to thrive. These new integrations are a natural extension of that mission, helping healthcare organizations to stay compliant, high-performing and focused on delivering exceptional care.' To learn more, please visit About EmpeonEmpeon is a human capital management platform designed exclusively for healthcare providers. The Company's fully integrated solution includes HR, payroll, scheduling, onboarding, and employee engagement—all tailored for the complexities of the healthcare industry. With an expanding partner marketplace and deep understanding of industry needs, Empeon empowers organizations to improve compliance, efficiency and employee satisfaction across the workforce lifecycle. Media Contacts Raquel Cona / Christina BavielloKCSA Strategic Communicationsrcona@ / cbaviello@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Wall Street Journal
22 minutes ago
- Wall Street Journal
Serena Williams Is the Surprising New Face of Weight-Loss Drugs
Serena Williams used GLP-1s to lose weight after having children, the tennis star says in a new ad campaign for online healthcare company Ro that aims to widen the pool of customers for the drugs. 'After kids, it's the medicine my body needed,' Williams tells viewers in one commercial, crediting GLP-1s for helping her lose 31 pounds. Williams, whose husband Alexis Ohanian is a Ro board member and investor, will also star in billboards and digital advertising as part of a promised multiyear promotional effort.
Yahoo
40 minutes ago
- Yahoo
A Rise In Surgical Robotics Could Send These 2 Healthcare Stocks Soaring
Key Points The robotic-assisted surgery market is expected to grow significantly in the coming years. Intuitive Surgical is the leader in this space and should profit from its rapid growth. Relative newcomer Medtronic could also cash in as it launches its Hugo device. 10 stocks we like better than Intuitive Surgical › The use of robotics in surgery is on the rise. The market was valued at $800 million in 2015, and has since risen to over $3 billion. One reason behind this rapid growth is that these robot systems utilize flexible, highly maneuverable instruments along with tiny cameras, allowing surgeons to perform complex procedures, often of the minimally invasive type. Compared to open surgeries, they result in less skin cutting, less bleeding, and less scarring. However, according to one survey, while 78% of U.S. surgeons are interested in the technology, many still aren't using it, leaving significant white space ahead. The increased adoption of surgical robotics could prove to be a massive tailwind for some healthcare leaders, including Intuitive Surgical (NASDAQ: ISRG) and Medtronic (NYSE: MDT). 1. Intuitive Surgical Intuitive Surgical is currently the leader in robotic surgery, thanks to a lineup of products that includes the Ion system, which aids in performing lung biopsies, and the renowned da Vinci system, indicated for a range of procedures in general surgery and many other areas. The da Vinci system is perhaps the best-known robot device on the market. It was first approved in 2000. Intuitive Surgical has since launched several newer versions of this product; the fifth generation was introduced last year. Having a first-mover advantage will help Intuitive Surgical in at least three ways as the market expands significantly. First, the company has established a brand name among physicians, who, like everyone else, tend to gravitate toward brands they trust, especially when lives are at stake. Second, since the da Vinci system has been in use for so long, a substantial amount of data from clinical trials and real-world applications demonstrates its efficacy. That's always an advantage in the healthcare industry. Third, Intuitive Surgical has a significant existing installed base. It ended the second quarter with 10,488 installed da Vinci systems, for a 14% year-over-year increase. These are expensive devices, so healthcare facilities won't switch unless they have a very strong incentive, which grants Intuitive Surgical a strong moat thanks to high switching costs. Meanwhile, the company has routinely recorded excellent financial results: Intuitive Surgical is facing some headwinds, including increased costs resulting from tariffs. Even with those, shares should perform well over the long run as the company's products continue to gain traction in the underpenetrated and rapidly growing robotic surgery industry. Despite its underperformance in the market this year, the stock still looks like a buy today. 2. Medtronic Medtronic is inching closer to making its grand entrance in the U.S. surgical robotics industry. Earlier this year, it reported that its device, the Hugo system, had been successful in clinical trials for urologic procedures. The company is now awaiting clearance from the U.S. Food and Drug Administration in that indication. Medtronic decided to pursue this opportunity precisely because it saw massive white space. A couple of years ago, management pointed out that less than 5% of procedures that could be performed with robotic assistance actually were at the time. The company is likely to seek additional approvals for its Hugo system. While it will take some time to have a meaningful impact, Medtronic's venture into this market could be an important addition over the long run for a company that has been struggling to grow its revenue at a satisfactory rate. Medtronic has made other changes to its business recently, including deciding to spin off its only consumer-facing segment, diabetes care, whose margins were lower than those of the rest of the business. Medtronic also faces tariff-related challenges, but the decision to separate from its diabetes unit should help. Furthermore, the company consistently delivers strong financial results despite economic and other challenges. That's due to its extensive and diversified portfolio of products across several therapeutic areas, and significant presence in 150 countries worldwide. Lastly, the company has a brilliant dividend track record; having increased its payouts for 48 consecutive years, it's closing in on Dividend King status. Medtronic's stock remains a top choice for income seekers, particularly given the significant growth opportunity its launch of the Hugo system is expected to provide. Should you invest $1,000 in Intuitive Surgical right now? Before you buy stock in Intuitive Surgical, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Intuitive Surgical wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $654,781!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,076,588!* Now, it's worth noting Stock Advisor's total average return is 1,055% — a market-crushing outperformance compared to 183% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 18, 2025 Prosper Junior Bakiny has positions in Intuitive Surgical. The Motley Fool has positions in and recommends Intuitive Surgical. The Motley Fool recommends Medtronic and recommends the following options: long January 2026 $75 calls on Medtronic and short January 2026 $85 calls on Medtronic. The Motley Fool has a disclosure policy. A Rise In Surgical Robotics Could Send These 2 Healthcare Stocks Soaring was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
